Skip to main content
EnglishEN
European Commission logo print header

Biomarkers in Atopic Dermatitis and Psoriasis

Project description

DEENESFRITPL

Predictive systems medicine resource for the management of atopic dermatitis and psoriasis

The goal of the EU-funded BIOMAP project is to provide a predictive systems medicine model of atopic dermatitis and psoriasis based on clinical and molecular profiling. The consortium will identify clinical determinants of relevant outcomes, elucidate disease mechanisms and deliver biomarkers for the prediction of disease trajectories and treatment response for use in drug development and clinical practice. BIOMAP will create a biospecimen and data resource of unprecedented scale and depth, accessible via a central data and analysis portal. The resource will support analyses in epidemiology, molecular profiling, skin biology and mathematical modelling to define disease and drug endotypes as well as critical lifestyle and environmental factors.

Objective

Our objective is to provide a taxonomic and predictive systems medicine model of Atopic Dermatitis and Psoriasis based on clinical and molecular profiling to (i) identify determinants of clinically relevant outcomes (disease manifestation, progression, comorbidity development and treatment response) (ii) improve understanding on shared and distinct disease mechanism(s) and associated signatures, and their relative importance in patient subpopulations and (iii) deliver biomarkers that identify disease trajectories and treatment response for use in drug development and clinical practice. BIOMAP will create a biospecimen and data resource of unprecedented scale and depth, accessible via a central data and analysis portal, harmonizing diverse, high quality, multi-dimensional datasets on skin and blood (whole and single cell), large scale population-based and trial data; parallel clinical research infrastructure will deliver supplementary material flexible to the needs of the consortium. This resource will be systematically analyzed using state-of-the-art methodologies in epidemiology, molecular profiling, skin biology and mathematical modelling to define disease and drug endotypes and how these interact with lifestyle and environmental factors. Selected, highly discriminatory, associated biomarkers will pass through a diagnostics pipeline (novel in-silico trial methods and assay development), ready for immediate translation. BIOMAP is expected to drive drug discovery to target causal mechanisms, shorten drug development pathways, and fundamentally change the diagnosis and management paradigm, from re-active to pro-active strategies that encompass disease biology and life-time trajectory, matching the intervention (prevention, modification of risk factors, therapeutics) with endotypes. Clinically annotated endotypes and associated biomarkers will identify when, in whom and how to intervene to minimize disease impact and improve outcomes.

Fields of science

Keywords

Programme(s)

Topic(s)

Call for proposal

H2020-JTI-IMI2-2017-13-two-stage

See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL
Net EU contribution
€ 1 478 387,00
Address
OLSHAUSENSTRASSE 40
24118 Kiel
Germany

See on map
Region
Schleswig-Holstein Schleswig-Holstein Kiel, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 2 332 141,00

Participants (35)

Share this page

Download

Last update: 17 April 2024

My Booklet

Permalink: https://cordis.europa.eu/project/id/821511

European Union, 2024